A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

Conditions: Breast Cancer Interventions: Drug: First-line Ribociclib + endocrine therapy; Drug: First-line endocrine therapy; Drug: First-line chemtherapy Sponsors: Novartis Pharmaceuticals Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials